Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03999515 · ClinicalTrials.gov registry record · Phase 2
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03999515 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 3 participants.
The verdict
NCT03999515, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase II trial studies how well erdafitinib in combination with abiraterone acetate or enzalutamide works in treating patients with double negative prostate cancer. Erdafitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Testosterone can cause the growth of prostate cancer cells. Abiraterone acetate lowers the amount of testosterone made by the body. This may help stop the growth of tumor cells that need testosterone to grow. Enzalutamide blocks the use of testosterone by the tumor cells. Giving erdafitinib with abiraterone acetate or enzalutamide may work better in treating patients with prostate cancer compared to abiraterone acetate or enzalutamide alone.
Interventions
- DRUG Enzalutamide
- DRUG Abiraterone Acetate
- DRUG Erdafitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-04-27 |
| Est. Completion | 2021-06-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03999515
The ClinicalTrials.gov registry entry for NCT03999515 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Enzalutamide is the first listed.
NCT03999515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03999515 about?
NCT03999515 is a clinical study titled "Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer". This phase II trial studies how well erdafitinib in combination with abiraterone acetate or enzalutamide works in treating patients with double negative prostate cancer. Erdafitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Testosterone can cause the ...
What is the current status of trial NCT03999515?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2020-04-27. Estimated completion is 2021-06-06.
What interventions are being tested in trial NCT03999515?
The interventions under investigation include: Enzalutamide (DRUG), Abiraterone Acetate (DRUG), Erdafitinib (DRUG).
Who is sponsoring clinical trial NCT03999515?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.